Wednesday, April 20, 2016
Onkos Surgical and Vivex Biomedical, Inc. have come together to provide a portfolio of tissue products to support the needs of musculoskeletal oncologists and their patients. This commitment strengthens Onkos Surgical’s ability to enhance outcomes, decrease complications and improve recovery following musculoskeletal tumor and limb salvage surgery.
“The addition of this portfolio of hard and soft tissue biologics increases our ability to support the entire spectrum of surgical care for this patient population, said Patrick Treacy, Co-founder and CEO of Onkos Surgical. “We are excited about this partnership with Vivex. Their dedication to developing regenerative therapies is a wonderful complement to Onkos Surgical’s focus on the needs of the surgeons and caregivers who dedicate their lives to the surgical treatment of cancer.”
According to H. Thomas Temple, M.D., Professor and Senior Vice President for Translational Research and Economic Development at NOVA Southeastern University and Medical Director of the University of Miami Tissue Bank, “Having a biologic portfolio that contains traditional bone and soft tissue grafts as well as robust stem cells and unique tissue scaffolds will expand reconstructive outcomes and transform the way we think about complex reconstruction following tumor resection. This is especially true for children with malignant bone tumors. Onkos Surgical is bridging biologics and implants and filling an unmet need in orthopaedics for patients who need complex reconstructions that optimize function.”
“Associations with innovative industry leaders like Onkos Surgical furthers our vision of enhancing the quality of patient care”, added Tracy Anderson, President and CEO of Vivex Biomedical, Inc. “We look forward to growing our relationship with Onkos Surgical.”
Source : onkossurgical.com
